Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) insider Linda Llewelyn sold 648 shares of the stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $16.06, for a total value of $10,406.88. Following the transaction, the insider now owns 58,029 shares in the company, valued at approximately $931,945.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Linda Llewelyn also recently made the following trade(s):
- On Wednesday, June 15th, Linda Llewelyn sold 648 shares of Health Catalyst stock. The stock was sold at an average price of $12.20, for a total value of $7,905.60.
- On Monday, May 16th, Linda Llewelyn sold 1,860 shares of Health Catalyst stock. The stock was sold at an average price of $15.87, for a total value of $29,518.20.
Health Catalyst Stock Performance
NASDAQ:HCAT opened at $16.03 on Friday. Health Catalyst, Inc. has a one year low of $11.25 and a one year high of $59.50. The stock has a market cap of $868.67 million, a PE ratio of -5.17 and a beta of 1.07. The stock has a 50 day moving average price of $14.84 and a 200 day moving average price of $21.89.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the company. BTIG Research decreased their target price on Health Catalyst from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 25th. Canaccord Genuity Group decreased their target price on Health Catalyst from $35.00 to $17.00 in a research report on Wednesday, May 11th. Citigroup decreased their target price on Health Catalyst from $45.00 to $25.00 in a research report on Wednesday, May 11th. Royal Bank of Canada decreased their target price on Health Catalyst from $35.00 to $19.00 in a research report on Wednesday, May 11th. Finally, Piper Sandler decreased their target price on Health Catalyst from $38.00 to $21.00 in a research report on Wednesday, May 11th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Health Catalyst has a consensus rating of “Buy” and an average price target of $35.25.
Institutional Investors Weigh In On Health Catalyst
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Stratos Wealth Partners LTD. acquired a new stake in Health Catalyst during the first quarter worth $2,287,000. abrdn plc increased its stake in Health Catalyst by 10.1% during the fourth quarter. abrdn plc now owns 1,097,447 shares of the company’s stock worth $43,481,000 after acquiring an additional 100,829 shares during the last quarter. Renaissance Technologies LLC increased its stake in Health Catalyst by 39.6% during the fourth quarter. Renaissance Technologies LLC now owns 279,369 shares of the company’s stock worth $11,069,000 after acquiring an additional 79,300 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Health Catalyst by 20.1% during the first quarter. Exchange Traded Concepts LLC now owns 83,034 shares of the company’s stock worth $2,170,000 after acquiring an additional 13,907 shares during the last quarter. Finally, Swiss National Bank increased its stake in Health Catalyst by 13.6% during the fourth quarter. Swiss National Bank now owns 95,100 shares of the company’s stock worth $3,768,000 after acquiring an additional 11,400 shares during the last quarter. Institutional investors and hedge funds own 97.53% of the company’s stock.
About Health Catalyst
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.
- Get a free copy of the StockNews.com research report on Health Catalyst (HCAT)
- Salesforce Stock is a Resilient Best-of Breed CRM Play
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Use High Beta Stocks to Maximize Your Investing Profits
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Why Will Highly-Valued Tesla Move Higher? Results
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.